NEW YORK, March 14 – Bioinformatics company Genomica said Wednesday it had appointed William Rich, CEO of Ciphergen Biosystems, to its board of directors, signaling the company’s growing interest in the field of proteomics.

"His experience in the industry in general and, in particular, the emerging field of protein-based biology research known as proteomics, will help us as we expand our product line and functionality," Teresa Ayers, CEO of Genomica, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.